Clinical Trials Sponsored by Angstrom Pharmaceuticals

Total 19532 results

Lexicon Pharmaceuticals

Completed

Efficacy, Safety, and PK of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1)

Diabetes | Diabetic Peripheral Neuropathy

United States
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Urothelial Carcinoma

United States, Spain
Inovio Pharmaceuticals

Active, not recruiting

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Glioblastoma

United States
Jazz Pharmaceuticals

Completed

A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

Multiple Sclerosis | Spasticity

United Kingdom
Titan Pharmaceuticals

Terminated

Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole

Parkinson Disease

United States
Jazz Pharmaceuticals

Completed

A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis

Multiple Sclerosis

United Kingdom
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
BioCryst Pharmaceuticals

Active, not recruiting

A Long Term Safety Study of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria | PNH

United Kingdom, Austria, South Africa
Santhera Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Raxone in LHON Patients (LEROS)

Leber's Hereditary Optic Neuropathy (LHON)

United States, United Kingdom, Spain, Poland, Austria, Belgium, Bulgaria, Germany, Italy, Portugal
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors

Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
SymBio Pharmaceuticals

Completed

Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma

Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL

Japan
Jazz Pharmaceuticals

Completed

Sativex Thorough QT/QTc Study

Effects of Sativex on ECG

Canada
Concert Pharmaceuticals

Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Alopecia Areata

United States, Canada
Marinus Pharmaceuticals

Completed

Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) (TSC)

Tuberous Sclerosis

United States
Intercept Pharmaceuticals

Terminated

Obeticholic Acid in Pediatric Subjects With Biliary Atresia (CARE)

Biliary Atresia

Israel, United Kingdom, Poland, Belgium, France, Germany, Italy, Netherlands, Spain
X4 Pharmaceuticals

Completed

Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States, Korea, Republic of
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Regeneron Pharmaceuticals

Completed

Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

Severe Hypertriglyceridemia (sHTG)

United States, Canada, Italy, United Kingdom
Ferring Pharmaceuticals

Completed

FIRMAGON Intensive Drug Monitoring Protocol

Prostate Cancer

China
Dizal Pharmaceuticals

Active, not recruiting

DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation

Non-Small Cell Lung Cancer

China
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)

Immunoglobulin A Nephropathy | Membranous Nephropathy | Complement 3 Glomerulopathy

France, Italy, Spain, United Kingdom
Endo Pharmaceuticals

Completed

Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity

Laxity; Skin | Cellulite | Edematous Fibrosclerotic Panniculopathy

United States
Jazz Pharmaceuticals

Completed

A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients

Multiple Sclerosis | Spasticity

Czechia
Jazz Pharmaceuticals

Completed

An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients

Multiple Sclerosis

United Kingdom
Regeneron Pharmaceuticals

Completed

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Melanoma

United States
Alexion Pharmaceuticals

Terminated

An Efficacy and Safety Study of Ravulizumab in ALS Participants

Amyotrophic Lateral Sclerosis | ALS

United States, Spain, Italy, Belgium, Canada, Switzerland, Australia, Germany, Denmark, Israel, Sweden, France, Ireland, United Kingdom, Japan, Netherlands, Poland
Cornerstone Pharmaceuticals

Completed

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Pancreatic Cancer Metastatic

United States, Korea, Republic of, France, Israel, Germany, Belgium
Jazz Pharmaceuticals

Completed

An Observational Post-Marketing Safety Registry of Sativex®

Multiple Sclerosis | Diabetes | Cancer | Neuropathic Pain
Jazz Pharmaceuticals

Completed

A Study of GWP42006 in People With Focal Seizures - Part B

Epilepsy | Focal Seizures

Italy, Poland, United Kingdom, Spain, Hungary, Czechia
Jazz Pharmaceuticals

Completed

A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years

Cerebral Palsy

Czechia, Israel, United Kingdom
Regeneron Pharmaceuticals

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Healthy

Belgium
Botanix Pharmaceuticals

Completed

A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

Hyperhidrosis
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
Concert Pharmaceuticals

Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Hepatic Impairment

United States
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Completed

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

Japan
Vanda Pharmaceuticals

Completed

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

Smith-Magenis Syndrome | Circadian

United States
Inovio Pharmaceuticals

Withdrawn

Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers

Coronavirus Infection
SymBio Pharmaceuticals

Withdrawn

Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

Japan
SymBio Pharmaceuticals

Terminated

Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

Postoperative Pain

Japan
X4 Pharmaceuticals

Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Waldenstrom's Macroglobulinemia

United States, Greece
Arrowhead Pharmaceuticals

Terminated

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

Cystic Fibrosis, Pulmonary

Australia, New Zealand
Inovio Pharmaceuticals

Completed

REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Cervical Dysplasia | Cervical High Grade Squamous Intraepithelial Lesion | HSIL

United States, Spain, Lithuania, Estonia, South Africa, Argentina, Brazil, Finland, Poland, Puerto Rico
Alexion Pharmaceuticals

Completed

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease

United Kingdom, United States
Arena Pharmaceuticals

Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) (CAPTIVATE)

Irritable Bowel Syndrome

United States
Jazz Pharmaceuticals

Completed

An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Epilepsy

Spain, United Kingdom
Aerie Pharmaceuticals

Completed

A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy (Fuchs)

Corneal Edema

United States
Ferring Pharmaceuticals

Completed

Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea

Ulcerative Colitis

Korea, Republic of
Marinus Pharmaceuticals

Completed

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601 (0602)

Epilepsy, Complex Partial

United States
Jazz Pharmaceuticals

Terminated

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome (ARCH)

Rett Syndrome | RTT

United States, Spain, Italy, United Kingdom

Clinical Trials Sponsored by Angstrom Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations